Reuters: Regulatory News: Medivation, Astellas prostate cancer drug meets trial goals

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

50% off Print Subscription of USA Today Get the news delivered to your doorstep. Lock in the savings and receive USA Today for just $0.75 a day. From our sponsors

Medivation, Astellas prostate cancer drug meets trial goals Oct 22nd 2013, 11:08 Tue Oct 22, 2013 7:08am EDT Oct 22 (Reuters) - Medivation Inc and its Japanese partner Astellas Pharma Inc said a late-stage trial of their experimental prostate cancer drug met the main goal of improving patients' survival. An independent safety committee monitoring the trial recommended the trial be stopped and patients be treated with the experimental drug enzalutamide, the companies said in a joint statement.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions